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ABSTRACT    
 
Background: No prior studies have characterized long-term patterns of opioid use regardless of 
source or reason for use among patients with HIV (PWH). We sought to identify trajectories of self-
reported opioid use and their correlates among a national sample of PWH engaged in care. 
 
Setting: Veterans Aging Cohort Study, a prospective cohort including PWH receiving care at eight US 
Veterans Health Administration (VA) sites.  
 
Methods: Between 2002 and 2018, we assessed past year opioid use frequency based on self-
reported “prescription painkillers” and/or heroin use at baseline and follow-up. We used group-
based trajectory models to identify opioid use trajectories and multinomial logistic regression to 
determine baseline factors independently associated with escalating opioid use compared to stable, 
infrequent use.  
 
Results: Among 3,702 PWH, we identified four opioid use trajectories: 1) no lifetime use (25%); 2) 
stable, infrequent use (58%); 3) escalating use (7%); and 4) de-escalating use 11%).  
In bivariate analysis, anxiety; pain interference; prescribed opioids, benzodiazepines and 
gabapentinoids; and marijuana use were associated with escalating opioid group membership 
compared to stable, infrequent use. In multivariable analysis, illness severity, pain interference, 
receipt of prescribed benzodiazepine medications and marijuana use were associated with escalating 
opioid group membership compared to stable, infrequent use.  
  
Conclusion: Among PWH engaged in VA care, one in 15 reported escalating opioid use. Future 
research is needed to understand the impact of psychoactive medications and marijuana use on 
opioid use and whether enhanced uptake of evidence-based treatment of pain and psychiatric 
symptoms can prevent escalating use among PWH.  
 




The opioid epidemic continues unabated with risk for global spread.1-4 Among patients with 
HIV (PWH), the opioid epidemic is threatening improved survival seen in recent decades. Between 
2011 and 2015, while the overall death rate for PWH in the United States decreased by 13%, the opioid 
overdose death rate increased concurrently by 42%.5 This trend may be driven, in part, by the fact 
that PWH are commonly prescribed opioids for pain,6 which increases risk of overdose6-8 and extra-
medical prescription opioid use.9 Defined as use of prescription opioids for indications other than 
those medically prescribed, in a manner other than prescribed (e.g. higher dose than prescribed), or 
without a prescription,9,10 extra-medical prescription opioid use, in turn, is a strong, independent 
predictor of heroin initation.11    
Despite these concerns, until recently, there have been insufficient efforts to promote more 
judicious opioid prescribing for chronic pain and attention to addressing unsafe patterns of opioid 
use in HIV clinical settings.12-20 Prior studies of opioid use among PWH lack comprehensive 
assessment of self-reported opioid use regardless of source of opioid and reason for use; they 
generally focused on prescribed opioid use (i.e., based on pharmacy data),6,8,21 self-reported extra-
medical opioid use ,22-26 or the relationship between prescribed opioids and extra-medical opioid 
use.9,27 Moreover, these prior studies did not have self-reported data linked with pharmacy data to 
robustly evaluate the impact of prescribed opioids or psychoactive medications for common 
comorbidities associated with opioid use  (i.e., prescribed benzodiazepines, gabapentinoids, and 
antidepressants).28-30 Importantly, psychoactive medications may reinforce31,32 or diminish opioid 
effects,33 and ultimately impact opioid-related risks, including death.26,34,35  
Thus, using data on a national cohort of PWH engaged in care and containing self-reported 
and linked pharmacy data, we sought to characterize patterns of self-reported opioid (including 
prescription opioid and heroin) use, regardless of reason and source, over time and the associated 




 The Veterans Aging Cohort Study (VACS) survey study, is a longitudinal, multi-site study of 
patients with and without HIV receiving care within the Veterans Health Administration (VA) in 
Manhattan/Brooklyn, New York; Bronx, New York; Pittsburgh, Pennsylvania; Atlanta, Georgia; 
Houston, Texas; Baltimore, Maryland; Washington, D.C.; and Los Angeles, California.36 Data sources 
include approximately annual patient surveys linked to VA electronic health record data including 
diagnoses, laboratory, and pharmacy data, as well as administrative data. The Institutional Review 
Boards at Yale University, VA Connecticut Healthcare System and each participating site approved 
the study.  
Study Population 
  
 For this analysis, we used data from seven survey waves completed between 2002 and 2018. 
We included patients with a HIV diagnosis and excluded those who were missing all self-reported 
items on opioid use during the study period.      
 Self-reported Opioid Use 
 
 We defined  opioid use based on self-reported prescription opioid and heroin use as assessed 
during the baseline 2002 and follow-up surveys initially launched in 2003, 2004, 2008, 2009, 2011, and 
2012 (Supplementary Figure 1).11 Participants were provided a list of substances (e.g., cocaine, 
marijuana) and asked: For each of the following drugs, please fill in the oval that best indicates how 
often in the past 12 months you have used each drug. Response options include the following: have 
never tried; no use in the last year; less than once a month; 1-3 times a month; 1-3 times a week; 4-6 times 
a week; every day. Opioid use was considered to be present if either prescription opioid and/or heroin 
use was endorsed. In the baseline 2002, frequency of prescription opioid and heroin use was 
assessed with a single item, while in subsequent surveys, use was assessed separately. Frequency of 
opioid use was defined based on whichever opioid was most frequently used.   
Covariates  
Based on existing literature, we examined sociodemographic, clinical and behavioral 
correlates of opioid use.23,28,29 Variables were assessed based on self-report and 
clinical/administrative data, including pharmacy fill/refill data, billing (diagnostic codes documented 
in the year prior to or day of baseline survey data completion as applicable) and registry data. 
Sociodemographic variables included age, gender, race and ethnicity, education, marital 
status, housing instability, location of residence (based on rural urban commuting codes37),  and 
annual household income.  
Clinical and behavioral variables included HIV-related factors: antiretroviral therapy receipt, 
(by receipt of >3 antiretroviral agents excluding boosters using pharmacy fill/refill data); CD4 cell 
count; HIV viral load; and VACS Index Score 2.0. HIV viral load was considered undetectable if <500 
copies/mL consistent with standards during the start of the observation period. VACS Index 2.0 is a 
validated measure of morbidity and mortality based on age, HIV viral load, CD4 cell count, white 
blood cell count, aspartate aminotransferase, alanine aminotransferase, platelets, creatinine, 
hepatitis C status, albumin, and body-mass index38,39 VACS Index 2.0 scores typically range from 20 to 
100, although extremes of 0 to 160 are possible. Each 5 point increment is associated with 30% 
increased risk of death.38 Cancer was defined as history of any cancer, excluding non-melanoma skin 
cancers, based on data available in the national VA Cancer Registry.40  
Symptoms hypothesized to be associated with opioid use were assessed by self-report.23 
Anxiety was assessed by the HIV Symptoms Index item,41 which asks whether the respondent felt 
nervous or anxious during the past 4 weeks and how much they were bothered by these feelings; 
responses were categorized as absent (I do not have this symptom or I have this symptom and it 
doesn’t bother me] or present (It bothers me a little, it bothers me, or it bothers me a lot).42 Depressive 
symptoms was defined as present based on a Patient Health Questionnaire-9 (PHQ-9) score of 
>10.43,44 Pain interference was assessed with one item from the 12-item short-form self-report scale 
(SF-12) of health-related quality of life that asked: During the past 4 weeks, how much did pain 
interfere with your normal work (including both work outside the home and housework)? Response 
options were categorized as binary variable (not at all or a little bit vs. moderately, quite a bit, or 
extremely).45 
To capture patient receipt of medically prescribed opioids, based on outpatient VA pharmacy 
fill and refill dates in the year prior to the baseline survey date, we determined receipt of prescribed 
oral and transdermal opioids (i.e., excluding buprenorphine and methadone for opioid use disorder) 
consistent with our prior methods.9,46 Prescribed opioid receipt was characterized based morphine 
equivalent daily dose (low dose: <50mg, high dose: >50mg47) and duration (short-term: <90 days 
supplied, long-term: >90 days supplied) to create a composite, mutually exclusive 5-level variable. We 
additionally examined duration of receipt of other prescribed psychoactive medications, including 
benzodiazepines, gabapentinoids and antidepressants, given they are commonly prescribed for 
conditions associated with opioid use, may alter opioid effects, and may be used extra-medically (see 
Supplementary Table 1).30-33,48,49  
Self-reported substance use variables included tobacco use based on current cigarette 
smoking and unhealthy alcohol use assessed with the Alcohol Use Disorders Identification Test-
Consumption (AUDIT-C) questionnaire score of >3 for women and >4 for men.50 Non-opioid drug use, 
including marijuana (marijuana or hashish) and stimulant use (cocaine or crack and stimulants 
[amphetamines, uppers, speed, crank, crystal, meth, bam]) was assessed similarly to opioid use. 
Participants were categorized as reporting non-opioid past year drug use if they endorsed at least 
monthly use. Opioid use disorder (OUD) was assessed based on the presence of inpatient or 
outpatient International Classification of Diseases, Ninth Revision (ICD-9) codes for opioid abuse 
and/or opioid dependence in the year prior to the baseline survey   
Statistical Analysis   
 We examined patterns of responses to the survey items. For opioid and non-opioid drug use, 
if a participant responded that they have never tried the given substance on a survey following a 
survey on which they reported use, they were recoded as having no use in the last year (i.e. since the 
last survey). We then used descriptive characteristics to examine patterns of frequency of 
prescription opioid and heroin use by survey wave and determine the baseline characteristics of our 
sample, using Chi-square and Wilcoxon rank sum test as appropriate.   
Consistent with our prior work,51-53 we next used a semi-parametric, group-based method to 
fit opioid use trajectories.54,55 Models were implemented using Proc TRAJ,54,55 a procedure that first 
sorts each participant’s set of reported opioid use frequency responses into longitudinal patterns. 
Then, group-based trajectories are estimated based on the number and shape of groups provided a 
priori, and by using a maximum likelihood procedure.  The procedure then calculates each 
individual’s probability of belonging to each trajectory and assigns them to the trajectory with the 
highest probability of membership. The strengths of this approach are that all available data from 
each individual are used to estimate participants’ trajectories and that the individuals with missing 
data are also included.55 We used an enhanced modeling approach where attrition is modeled 
simultaneously with the trajectory group as a function of time before drop out.56 This approach has 
been increasingly applied to address non-random attrition, including missing data due to death.57-59 
Specifically, the DROPOUT option in Proc TRAJ was used to model the probability of dropout for 
each group as a function of measurement before dropout. To determine the number of groups and 
trajectory shapes, we examined model fit statistics (i.e., the Bayesian information criterion [BIC], 
with BIC values closer to zero indicating a better fit), significance of polynomial terms, and aimed for 
models in which each group membership was greater than 5% of the modeled sample.52,54 We also 
examined the distribution of posterior group membership probabilities to ensure adequate model fit 
with a median probability greater than 0.70. Based on these criteria, the model fit was best when we 
used a zero-inflated Poisson outcome distribution allowing for trajectories to take a quadratic form.  
Estimated trajectories and observed mean frequency of opioid use at each assessment for each 
trajectory group were then computed and plotted using TRAJPLOT.60 The time scale was based on 
years since baseline, with each survey being administered on an approximately annual basis.  
 We then examined bivariate associations between baseline participant characteristics and 
trajectory group membership, examining global p-values for comparisons across all four groups and 
separate comparisons between the escalating vs. stable, infrequent group given our specific interest 
to understand characteristics associated with escalating patterns of use compared to lower and 
more stable use patterns. 
Lastly, we created a series of multinomial models using block-wise sequential regression to 
identify independent predictors associated with group membership, including only independent 
variables with a p<0.05 for the global comparisons in bivariate analyses. The first model (a.) included 
sociodemographic characteristics; we then sequentially added (b.) clinical characteristics, then (c.) 
prescribed opioid and non-opioid psychoactive medications, and finally (d.) other substance use.  We 
examined model statistics using Akaike information criterion (AIC) and evaluated for collinearity 
using the variance inflation factor (VIF). All statistical analyses were conducted in SAS (version 9.4) 
and p values <0.05 were considered statistically significant.       
 
RESULTS 
Baseline participant characteristics   
 Among VACS survey participants with HIV (N=3,728), we excluded those missing all self-
reported items on opioid use during the study period (n=26), yielding a final analytic sample of 3,702 
participants. Over the 16-year study, the mean years of follow-up was 6 (standard deviation 
[SD]=4.2), ranging from 5.5 to 10.0 across trajectory groups and 38% died (Table 1). Across follow-up 
survey waves, 13-18% reported past year prescription opioid use and 2-4% reported past year heroin 
use (Figures 1a-1b). 
The mean age was 50 years old (SD=9) and the sample was nearly all men (97%), and 
predominantly Black (67%). Sixty percent had completed some college, 41% were married or living 
with a partner, 42% had experienced housing instability, 95% lived in urban settings, and 51% had an 
annual household income less than $11,999. Most had received antiretroviral therapy (77%), had a 
median CD4 cell count of 378 cells/mm3 (interquartile range [IQR]=227, 562]), 58% had an 
undetectable HIV viral load, and the median VACS Index 2.0 score was 58 (IQR=48, 70). Thirty-eight 
percent had HCV co-infection and 19% received a diagnosis of cancer.       
 Psychiatric and pain symptoms, psychoactive medication receipt, and substance use were 
common. Thirty-eight percent reported bothersome levels of anxiety, 23% reported at least 
moderate levels of depression, and 34% had at least moderate pain interference. The proportion of 
participants with psychoactive medication receipt was: opioids 28%; benzodiazepines 14%; 
gabapentinoids 11%; and antidepressants 37% (supplementary Table 2). Seventy-seven percent 
reported smoking cigarettes, 37% screened positive for unhealthy alcohol use, 28% reported 
marijuana use, and 24% reported stimulant use in the past year. Nine percent had received a 
diagnosis of opioid use disorder.     
Group-Based Opioid Use Trajectory Models 
 The final four-group solution generated opioid use trajectories with distinct patterns: 1) no 
lifetime use (25%); 2) stable, infrequent use (58%); 3) escalating use (7%); and 4) de-escalating use (11%) 
(Figure 2).  The first two trajectories were best characterized with intercept and linear terms; the 
second two groups also included quadratic forms. The median probability of group membership in 
each group was 0.93, 0.96, 0.76, and 0.93, respectively, indicating good model fit.  
Factors associated with Opioid Use Trajectory Group  
 In bivariate analyses, education, marital status, housing instability, annual household income, 
CD4 cell count, VACS Index 2.0 score and hepatitis c virus co-infection varied across groups (all global 
p-values <0.05, Table 1). In addition, symptoms; receipt of prescribed opioids and other psychoactive 
medications (Figures 3a-2d, supplementary Table 2); and substance use all varied across groups (all 
global p-values <0.05).  In pair-wise comparisons, anxiety symptoms, pain interference, prescribed 
opioids, benzodiazepines and gabapentinoid receipt, and marijuana use were more common among 
those with escalating opioid use than those with stable, infrequent use (p-values <0.05). 
 In sequential, multivariable analyses, the AIC values improved with each subsequent model 
and the VIF was <2 for each variable; we, therefore, present results for the final model (Table 2).  Our 
findings suggested that education, and housing instability were independently associated with group 
membership.  Additionally, VACS Index 2.0 score; pain interference; receipt of prescribed opioids and 
antidepressants; and evidence of tobacco, unhealthy alcohol, marijuana, and stimulant use also 
varied by opioid use trajectory group membership (all global p-values <0.05). For example, cigarette 
use was more common in the de-escalating group (adjusted odds ratio [AOR] = 1.61, 95%CI: 1.07-2.41) 
and less common in those with no lifetime use (AOR = 0.50, 95%CI: 0.41-0.60) compared to those 
with stable, infrequent use. Further, measures of illness severity, pain interference, prescribed 
benzodiazepine medication duration and marijuana use varied among those with escalating opioid 
use compared to those with stable, infrequent use (p-values for pair-wise comparison <0.05). For 
instance, receipt of short-term and long-term prescribed benzodiazepines were more common in the 
escalating group (AOR = 1.58, 95%CI: 0.84 – 2.98 & AOR = 1.89, 95%CI: 1.09 – 3.29, respectively) 
compared to the stable, infrequent use.   
DISCUSSION 
 
To our knowledge, this is the first study to examine longitudinal patterns of self-reported l 
opioid use among PWH and with linked outpatient pharmacy data, including both prescribed opioids 
and other psychoactive medications commonly prescribed to PWH. Our study reveals several 
important findings. First, in this sample of patients engaged in care, up to nearly 1 in 5 patients 
reported past year opioid use and 1 in 15 patients had evidence of escalating opioid use. Second, 
escalating opioid use was associated with potentially modifiable factors, including physical and 
emotional symptoms, psychoactive medication receipt, and substance use, as well as key 
sociodemographic characteristics that highlight potentially vulnerable subpopulations. In a series of 
multivariable analyses, illness severity, pain interference, receipt of prescribed benzodiazepines and 
marijuana use were independently associated with escalating opioid use. HIV-related variables were 
not consistently associated with patterns of opioid use.       
 Our finding that up to nearly 20% of patients reported past year opioid use and 7% of patients 
had a pattern consistent with escalating opioid use is concerning. While some of this opioid use may 
reflect use of prescribed opioids (i.e., provided by a clinician) for treatment of pain, findings from the 
Medical Monitoring Project (MMP), a national surveillance study of PWH, demonstrated that 3% of 
the sample had extra-medical opioid use largely driven by extra-medical prescription opioids use.26 
Given these data from the MMP combined with those from other studies24,25,48,61 and a clinical 
context where opioid prescribing practices have been slowly changing,62 our data raise concern that 
a substantial number of individuals are exposed to opioids and at risk for escalating opioid use. This is 
concerning as opioid use, and particularly a pattern of escalating use, is likely associated with greater 
potential harms, including falls,63 infectious complications,46 addiction, and overdose. Our study 
results reinforce the importance of the US Preventive Services Task Force new recommendations for 
screening and identification of extra-medical opioid use,64 promotion of harm reduction services, and 
use of evidence-based OUD treatment, such as buprenorphine or methadone,13,18,65 among PWH 
engaged in care. 
 That escalating opioid use was more common among those with physical and emotional 
symptoms, and substance use is supported by prior work.26,29,61 These associations may be explained 
by common reasons driving opioid use, including a motivation to seek euphoria, treat pain and its 
associated negative affective responses, or self-medication of anxiety and depressive symptoms.23,66-
68 Accordingly, efforts to prevent escalating opioid use might focus on comprehensive evidenced-
based treatment of pain, mental health and substance use.69 While the VA as well as the Ryan White-
funded infrastructure facilitate access to mental health and substance use treatment for PWH, these 
conditions often go under-recognized and undertreated.70 Furthermore, the existence of and access 
to evidence-based treatments to address pain among PWH is generally lacking.71,72 Efforts to develop 
novel interventions for PWH with pain are actively underway and will likely be an essential part of the 
solution to help prevent development of escalating opioid use among PWH.73  
 It is notable that, compared to those with stable, infrequent opioid use, PWH with escalating 
opioid use tended to receive psychoactive prescribed medications, including opioids, 
benzodiazepines, gabapentinoids and antidepressants again suggesting the influence of pain and 
other psychological symptoms and/or the potential synergistic euphorigenic effect of multiple CNS-
acting medications. Further, based on multivariable analyses, findings indicate that receipt of 
prescribed benzodiazepine medications were independently associated with escalating opioid use. In 
the time period of this study, prescribed opioids were often dispensed liberally in HIV treatment 
settings51 with limited adherence to guidelines for opioid prescribing, such as urine toxicology 
testing, opioid treatment agreements, limiting co-prescribing of other psychoactive medications 
(e.g., benzodiazepines) and optimal use of non-pharmacologic pain treatments.12,14 Release of 
guidelines for opioid prescribing by the Centers for Disease Control and Prevention and Infectious 
Diseases Society of America17,74 have stimulated more careful opioid prescribing.62 Whether non-
opioid psychoactive medication duration is a marker of symptom severity, treatment initiation or lack 
of response, or itself serves to promote escalating  opioid use warrants further investigation. 
Regardless, these findings are concerning given that these medications may also be used extra-
medically to promote euphoria and/or recover from opioid use,48,49 and in combination with opioids 
these drugs may contribute to risk of adverse events, particularly overdose.32,74-77     
 Nearly 80% had received antiretroviral medications in the year prior to baseline and this, nor 
HIV viral suppression varied by opioid use trajectory. CD4 cell count and overall illness severity by 
VACS Index 2.0 score, in contrast, were associated with opioid use trajectory. These findings may be 
explained by the fact that PWH receiving prescribed opioids may be more likely to be engaged in 
clinical care.15,16 To guide clinical practices and policies, future studies that further explore the 
interaction between prescribed opioid receipt, self-reported opioid use, and HIV-related outcomes 
over time are needed. In particular, studies are needed to determine the degree to which biological 
(e.g., gut homeostasis, immunosuppression)78-81 or behavioral (e.g., antiretroviral therapy non-
adherence) mechanisms drive associations between opioid exposure and HIV outcomes. We 
additionally found that marijuana use was consistently associated with opioid use over time and an 
independent predictor of escalating opioid use. Given expanding access to marijuana and suggestion 
that marijuana use may help decrease opioid use, it will be critical to further investigate longitudinal 
associations.82 
 Our study has some limitations. First, we defined frequency of opioid use based on the 
highest frequency of reported prescription opioid or heroin use over the prior 12 months, rather than 
summing these frequencies, with the assumption that individuals are typically using one form of 
opioid in a given day. Second, our findings may not be generalizable to non-Veteran populations or 
women. Third, these data may not reflect current shifting trends in opioid prescribing or the impact 
of the wider availability of illicitly manufactured fentanyl for extra-medical opioid use.  Fourth, as 
surveys were self-administered, there may have been variability in interpretation of the items among 
participants and over time with regards to what type of opioid use (i.e., medically prescribed or 
otherwise) was being ascertained. In particular, a relatively large proportion (34%) of participants 
endorsed no lifetime use following a report of some use in a prior survey. We chose to re-code these 
responses as no use in the last year. As such, there is likely some misclassification of participants 
grouped into the no lifetime use and stable, infrequent use categories. However, we expect the 
degree of misclassification to be low and nondifferential, since membership in the no lifetime use 
trajectory was strongly associated with no use of other substances (including tobacco and cocaine). 
Fifth, the de-escalating group had a higher proportion of participants who had died and shorter 
period of follow-up. However, a strength of our trajectory-based analysis is that individuals with 
missing data are included, and our approach accounts for non-random missing data, including from 
death and other reasons for dropout. Sixth, participants were assigned to the trajectory to which 
they had the highest posterior probability of membership. Although the posterior probabilities were 
generally high (above 0.90, indicating good model fit), there is likely some misclassification across 
trajectories, particularly for persons with lower probabilities of membership in one group over 
others. Lastly, our measures of psychoactive medication receipt were based on VA pharmacy data 
and thus do not capture non-VA medication.      
Conclusions 
 
To help mitigate the impact of the opioid epidemic among PWH, future efforts to limit 
escalating opioid use should focus on optimizing care of individuals with pain, mental health 
symptoms and other substance use. As opioid prescribing practices shift, future research is needed 
to elucidate the longitudinal associations between psychoactive medication receipt, marijuana use 
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Table 1. Sociodemographic and clinical characteristics associated with membership in group-based 


























Demographics        
Age, mean (SD) 49.8 (8.9) 49.5 (10.8) 49.8 (8.4) 49.4 (7.1) 50.6 (6.8) 0.109 0.501 
Gender, n (%)       0.780 0.784 
    Male 3604 (97.4) 875 (96.9) 2239 (97.5) 141 (97.2) 349 (97.8)   
   Female 98 (2.7) 28 (3.1) 58 (2.5) 4 (2.8) 8 (2.2)   
Race/ethnicity, n (%)      0.373 0.642 
     White 716 (19.3) 153 (16.9) 459 (20.0) 35 (24.1) 69 (19.3)   
     Black  2478 (66.9) 621 (68.8) 1525 (66.4) 92 (63.5) 240 (67.2)   
     Hispanic 355 (9.6) 98 (10.9) 210 (9.1) 13 (9.0) 34 (9.5)   
     Other 153 (4.1) 31 (3.4) 103 (4.5) 5 (3.5) 14 (3.9)   
Education, n (%)      0.0002 0.053 
     High school or  
     Less 
1476 (40.3) 347 (38.9) 905 (39.8) 46 (31.7) 178 (50.1)   
     Some college or  
     More 
2190 (59.7) 546 (61.1) 1368 (60.2) 99 (68.3) 177 (49.9)   
Marital status, n (%)      0.005 0.224 
     Never married 832 (22.8) 187 (21.1) 546 (24.1) 29 (20.3) 70 (19.8)   
     Married/living  
     with Partner 
1499 (41.1) 346 (39.1) 913 (40.3) 68 (47.6) 172 (48.7)   
     Divorced/  
     widowed 
1315 (36.1) 353 (39.8) 805 (35.6) 46 (32.2) 111 (31.4)   
Housing instability 
evera, n (%) 
1562 (42.4) 243 (27.1) 1043 (45.7) 73 (50.3) 203 (57.0) <0.0001 0.273 
Location of 
residence, n (%) 
     0.390 0.206 
     Urban 3479 (95.0) 853 (95.2) 2155 (94.9) 134 (93.1) 337 (96.0)   
     Suburban 103 (2.8) 20 (2.2) 71 (3.1) 4 (2.8) 8 (2.3)   
     Rural  80 (2.2) 23 (2.6) 45 (2.0) 6 (4.2) 6 (1.7)   
Annual income, n 
(%)  
     <0.0001 0.195 
     <$11,999 1822 (50.9) 359 (41.5) 1164 (52.2) 73 (51.4) 226 (65.3)   
     $12,000 - $49,999 1494 (41.7) 437 (50.5) 885 (39.7) 63 (44.4) 109 (31.5)   
     >=$50,000 266 (7.4) 69 (8.0) 180 (8.1) 6 (4.2) 11 (3.2)   
HIV-related factors        
     Antiretroviral  
     therapy receipt, n     
     (%) 
2855 (77.1) 721 (79.8) 1753 (76.3) 114 (78.6) 267 (74.8) 0.115 0.526 
     CD4 cell count,  
     cells/mm3,  












     HIV viral load  
     <500 copies/mL,  
2113 (57.9) 547 (61.3) 1295 (57.2) 80 (55.2) 191 (54.7) 0.091 0.633 
Table 1
     n (%) 
     VACS Index 2.0  
     score,b median  
     (IQR) 
58 (48, 70) 55 (45, 64) 58 (48, 70) 56 (47, 65) 64 (54, 78) <0.0001 0.110 
Other health 
conditions and 
status, n (%) 
       
     HCV positive  1415 (38.2) 147 (16.3) 987 (43.0) 70 (48.3) 211 (59.1) <0.0001 0.211 
     Any cancer 701 (18.9) 169 (18.7) 424 (18.5) 31 (21.4) 77 (21.6) 0.467 0.381 
     Anxiety     
     Symptomsc 
1349 (37.5) 258 (29.4) 850 (38.0) 66 (47.8) 175 (50.6) <0.0001 0.022 
     Depressive  
     Symptomsd 
828 (22.6) 141 (15.8) 513 (22.5) 41 (28.5) 133 (37.5) <0.0001 0.099 
     Pain  
     Interferencee 
1244 (33.9) 222 (24.8) 746 (32.8) 70 (48.3) 206 (58.2) <0.0001 0.0001 
Other substance 
use, n (%) 
       
     Smokes  
     Cigarettes 
2839 (76.7) 560 (62.0) 1835 (79.9) 125 (86.2) 319 (89.4) <0.0001 0.064 
     Unhealthy  
     alcohol usef 
1352 (36.5) 257 (28.5) 896 (39.0) 61 (42.1) 138 (38.7) <0.0001 0.464 
     Marijuanag 1021 (27.6) 228 (25.3) 618 (26.9) 54 (37.2) 121 (33.9) 0.0007 0.007 
    Stimulants or  
     Cocaineg 
891 (24.1) 138 (15.3) 567 (24.7) 40 (27.6) 146 (40.9) <0.0001 0.433 
     Opioid use  
     Disorder 
337 (9.1) 5 (0.6) 197 (8.6) 18 (12.4) 117 (32.8) <0.0001 0.113 
Average follow-up 
years, mean (SD) 
6.2 (4.2) 6.5 (3.7) 5.9 (4.3) 10.0 (1.9) 5.5 (4.0) <0.0001 <0.0001 
Died during study 
period, n (%) 
1422 (38.4) 301 (33.3) 898 (39.1) 34 (23.5) 189 (52.9) <0.0001 0.0002 
Notes:  
a. reported “yes” to “Have you ever been without a permanent address that you call home?”  
b. VACS Index 2.0 score, validated measure of morbidity and mortality, based on HIV biomarkers (CD4 cell 
count, HIV viral load), hemoglobin, white blood cell count, liver fibrosis by FIB-4, hepatitis C status (HCV, based 
on antibody status and HCV RNA and diagnostic codes), albumin, kidney function by estimated glomerular 
filtration rate, and body mass index 
c. anxiety symptoms considered present if response included any of the following: “bothers me a little,” “it 
bothers me,” “it bothers me a lot” 
d. depressive symptoms, defined as present based on PHQ-9 score >9 
e. self-reported pain interference in daily life, defined as present based if response included any of the 
following: “moderately,” “quite a bit” or “extremely” 
f. alcohol use disorder identification test-consumption (AUDIT-C) – defined as score of >3 for women, >4 for 
men 
g. substance use considered present if response consistent with any use over the past 12 months 
 
 
Table 2. Factors associated with group-based extra-medical opioid use trajectories among patients 
with HIV engaged in care, final multinomial logistic regression model 



















Demographics       
Education     0.0125 0.061 
     High school or less Ref Ref Ref Ref   
     Some college or more 0.89 (0.74, 1.06) Ref 1.47 (0.99, 2.17) 0.75 (0.58, 0.97)   
Marital status     0.0811 0.316 
     Never married Ref Ref Ref Ref   
     Married/living with  
     Partner 
1.39 (1.10, 1.75) Ref 1.33 (0.83, 2.12) 1.14 (0.81, 1.62)   
     Divorced/widowed 1.35 (1.07, 1.70) Ref 0.96 (0.58, 1.59) 1.08 (0.75, 1.56)   
Housing instability ever 0.54 (0.45, 0.66) Ref 1.10 (0.75, 1.60) 1.14 (0.87, 1.50) <0.0001 0.576 
Annual income      0.1142 0.416 
     <$11,999 Ref Ref Ref Ref   
     $12,000 - $49,999 1.14 (0.94, 1.38) Ref 1.14 (0.77, 1.68) 0.91 (0.68, 1.22)   
     >=$50,000 0.73 (0.52, 1.04) Ref 0.64 (0.26, 1.57) 0.68 (0.33, 1.39)   
Health conditions and 
symptoms 
      
     VACS Index 2.0 in 10  
     point increments 
0.91 (0.86, 0.96) Ref 0.88 (0.78, 
0.98) 
1.14 (1.06, 1.23) <0.0001 0.031 
     Anxiety symptoms 0.97 (0.79, 1.19) Ref 1.07 (0.71, 1.61) 1.06 (0.79, 1.42) 0.9495 0.905 
     Depressive symptoms 0.89 (0.69, 1.14) Ref 1.01 (0.64, 1.58) 1.28 (0.94, 1.75) 0.2905 0.959 
     Pain interference 0.95 (0.77, 1.17) Ref 1.56 (1.05, 2.33) 1.42 (1.07, 1.89) 0.0121 0.025 
Prescribed medications       
     Opioid duration and  
     dose 
    <0.0001 0.750 
          None Ref Ref Ref Ref   
          Short-term + low dose 0.82 (0.65, 1.02) Ref 1.14 (0.74, 1.76) 1.39 (1.00, 1.93)   
          Shot-term + high dose 0.48 (0.20, 1.18) Ref 1.36 (0.40, 4.61) 1.78 (0.76, 4.16)   
          Long-term + low dose 0.56 (0.32, 0.98) Ref 0.87 (0.38, 2.03) 7.60 (5.08, 11.36)   
          Long-term + high    
          Dose 
0.24 (0.07, 0.81) Ref 1.95 (0.74, 5.14) 12.66 (7.25, 
22.10) 
  
     Benzodiazepine  
     Duration 
    0.1150 0.049 
          None Ref Ref Ref Ref   
          Short-term 0.84 (0.55, 1.28) Ref 1.58 (0.84, 2.98) 0.87 (0.53, 1.41)   
          Long-term 0.81 (0.56, 1.17) Ref 1.89 (1.09, 3.29) 0.79 (0.50, 1.26)   
     Antidepressant duration     0.0134 0.281 
          None Ref Ref Ref Ref   
          Short-term 0.68 (0.51, 0.92) Ref 1.28 (0.77, 2.12) 1.29 (0.90, 1.84)   
          Long-term 0.72 (0.57, 0.92) Ref 0.84 (0.53, 1.34) 1.03 (0.75, 1.42)   
     Gabapentinoid duration     0.0714 0.245 
          None Ref Ref Ref Ref   
          Short-term 0.59 (0.34, 1.02) Ref 1.14 (0.54, 2.42) 1.30 (0.78, 2.16)   
Table 2
Notes: AIC for overall model: 6118.74; AIC for group 2 and 3 only: 1016.06 
 
          Long-term 1.28 (0.85, 1.93) Ref 1.77 (0.95, 3.32) 1.58 (1.01, 2.46)   
Substance use       
     smokes cigarettes 0.50 (0.41, 0.60) Ref 1.40 (0.84, 2.35) 1.61 (1.07, 2.41) <0.0001 0.210 
     unhealthy alcohol use 0.71 (0.59, 0.86) Ref 1.05 (0.73, 1.51) 0.87 (0.67, 1.14) 0.0039 0.776 
     marijuana, any in past  
     year 
1.23 (1.00, 1.51) Ref 1.52 (1.03, 2.25) 0.93 (0.70, 1.25) 0.0425 0.035 
     cocaine or stimulant use,  
     any in past year  
0.73 (0.57, 0.94) Ref 1.09 (0.70, 1.68) 2.08 (1.55, 2.79) <0.0001 0.838 
Supplementary Table 1. Benzodiazepine, gabapentinoids, and antidepressant medication receipt  
Medication Class Specific Medications 
 
Benzodiazepines  alprazolam, chlordiazepoxide, clonazepam, 
clorazepate, diazepam, estazolam, eszopiclone, 
flurazepam, lorazepam, midazolam, oxazepam,  





Antidepressants  amitriptyline, amoxapine, bupropion, 
citalopram, clomipramine, desipramine, 
desvenlafaxine, doxepin, duloxetine, 
escitalopram, fluoxetine, fluvoxamine, 
imipramine, isocarboxazid, levomilnacipran, 
maprotiline, milnacipran, mirtazapine, 
nefazodone, nortriptyline, paroxetine, 
phenelzine sulfate, protriptyline, selegiline, 
sertraline, tranylcypromine, trazodone, 











Supplementary Table 2. Prescribed medications and associations with membership in group-based 
self-reported opioid use trajectories among patients with HIV  

























Prescribed opioids      <0.0001 0.010 
     None 2674 (72.2) 741 (82.1) 1682 (73.2) 93 (64.1) 158 (44.3)   
     Short-term 
     + low dose 
682 (18.4) 133 (14.7) 449 (19.6) 33 (22.8) 67 (18.8)   
     Shot-term 
     + high dose 
60 (1.6) 6 (0.7) 41 (1.8) 4 (2.8) 9 (2.5)   
     Long-term 
     + low dose 
198 (5.4) 18 (2.0) 92 (4.0) 8 (5.5) 80 (22.4)   
     Long-term 
     + high dose 




     <0.0001 0.001 
     None 3194 (86.3) 818 (90.6) 1985 (86.4) 110 (75.9) 281 (78.7)   
     Short-term 217 (5.9) 35 (3.9) 136 (5.9) 13 (9.0) 33 (9.2)   




     <0.0001 0.001 
     None 3309 (89.4) 840 (93.0) 2073 (90.3) 118 (81.4) 278 (77.9)   
     Short-term 164 (4.4) 19 (2.1) 106 (4.6) 10 (6.9) 29 (8.1)   




     <0.0001 0.062 
     None 2333 (63.0) 669 (74.1) 1421 (61.9) 76 (52.4) 167 (46.8)   
     Short-term 487 (13.2) 76 (8.4) 312 (13.6) 27 (18.6) 72 (20.2)   
     Long-term 882 (23.8) 158 (17.5) 564 (24.6) 42 (29.0) 118 (33.1)   
Note: Duration of medications defined based on days supplied in the year prior to baseline survey as 





Figure 1. Self-reported frequency of prescription opioid and heroin use by survey wave 
 
 
Note: Baseline 2002 survey (“0” in the legend) combined prescription opioid and heroin use into a 




















































































Figure 1b. Self-reported heroin use                                                











Figure 2. Group-based self-reported opioid use trajectories among patients with HIV (2002-2018) 
 
 
Note: Dashed lines represent estimated trajectories; solid lines represent observed frequency of 











































Time since baseline, years
No lifetime use (24.7%) Stable, infrequent use (58.1%)
Escalating use (6.6%) De-escalating use (10.6%)
Figure 2
Figure 3. Duration of medication receipt of a) prescribed opioids, b) benzodiazepines, c) 
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Self-reported opioid use trajectory
3a. Prescribed opioid duration 
by self-reported opioid use trajectory
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Self-reported opioid use trajectory
3b. Benzodiazepine duration 
by self-reported opioid use trajectory






Note: Duration of medications defined based on days supplied in the year prior to baseline survey as 
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Self-reported opioid use trajectory
3c. Gabapentinoid duration 
by self-reported opioid use trajectory
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Self-reported opioid use trajectory
3d. Antidepressant duration 
by self-reported opioid use trajectory
None Short term Long term
Supplementary Figure 1. Survey items to assess self-reported opioid use   
 
Notes: Example above taken from survey administered at follow-up 5 (www.vacohort.org). Opioid 
use was listed as opioids (heroin, morphine, codeine, opium) in the baseline survey and separately as 
heroin and prescription opioids (morphine, codeine, Vicodin, Percocet, OxyContin) in follow-up surveys. 
Opioid use was not assessed in this manner in the follow-up 3 survey.  
 
supplementary Figure 1
